To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea
Status:
Withdrawn
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety and efficacy of (0.02 mg EE as
betadex clathrate [β-CDC]) / 3 mg drospirenone (DRSP) for dysmenorrhea. In order to
appropriately evaluate the efficacy of EE(β-CDC)/DRSP the study was set up as a
placebo-controlled comparative study